Novo Nordisk Announces Major Price Cuts for Ozempic and Wegovy in US Market
Novo Nordisk has announced major price cuts for its popular medications Ozempic and Wegovy in the US market. The company will reduce Ozempic's list price by 34% and implement cuts of up to 50% on US list prices for both medications. These substantial reductions represent a significant strategic move to improve accessibility and address affordability concerns for these high-demand diabetes and weight-loss treatments.